Abstract
Vasoactive peptides such as angiotensin II and endothelin-1 as well as growth factors regulate vascular homeostasis through signaling pathways that are triggered in both normal and disease states. These vasoactive peptides and growth factors also increase the cellular levels of calcium which, through calcium binding effector systems initiating the downstream signaling and physiological responses in target cells. A multifunctional calcium-calmodulin-dependent protein kinase II (CaMKII) has emerged as an important transducer of vasoactive peptide-induced responses in vascular smooth muscle cells (VSMC). The catalytic activity of CaMKII can be stimulated by autophosphorylation and oxidation leading to the activation of signaling events that mediate growth, proliferation, migration, and gene transcription in VSMC. Pharmacological and gene deletion approaches have demonstrated a requirement of CaMKII in mediating the mitogen- activated protein kinase and phosphatidyl-inositol 3-kinase/protein kinase B signalling, as well as the proliferative, migratory and transcriptional responses of vasoactive peptides. In addition, a potential involvement of hyperactive CaMKII in animal models of vascular disease has also been reported. Therefore, this review aims to highlight the role of CaMKII in mediating signaling and physiological responses in VSMC and discuss its potential role in vascular pathophysiology.
Keywords: Angiotensin-II, CaMKII, endothelin-1, G-protein-coupled receptor, hypertrophy, migration, proliferation, VSMC.
Current Vascular Pharmacology
Title:Ca2+/Calmodulin-Dependent Protein Kinase- II in Vasoactive Peptide- Induced Responses and Vascular Biology
Volume: 12 Issue: 2
Author(s): Estelle R. Simo Cheyou, Ali Bouallegue and Ashok K. Srivastava
Affiliation:
Keywords: Angiotensin-II, CaMKII, endothelin-1, G-protein-coupled receptor, hypertrophy, migration, proliferation, VSMC.
Abstract: Vasoactive peptides such as angiotensin II and endothelin-1 as well as growth factors regulate vascular homeostasis through signaling pathways that are triggered in both normal and disease states. These vasoactive peptides and growth factors also increase the cellular levels of calcium which, through calcium binding effector systems initiating the downstream signaling and physiological responses in target cells. A multifunctional calcium-calmodulin-dependent protein kinase II (CaMKII) has emerged as an important transducer of vasoactive peptide-induced responses in vascular smooth muscle cells (VSMC). The catalytic activity of CaMKII can be stimulated by autophosphorylation and oxidation leading to the activation of signaling events that mediate growth, proliferation, migration, and gene transcription in VSMC. Pharmacological and gene deletion approaches have demonstrated a requirement of CaMKII in mediating the mitogen- activated protein kinase and phosphatidyl-inositol 3-kinase/protein kinase B signalling, as well as the proliferative, migratory and transcriptional responses of vasoactive peptides. In addition, a potential involvement of hyperactive CaMKII in animal models of vascular disease has also been reported. Therefore, this review aims to highlight the role of CaMKII in mediating signaling and physiological responses in VSMC and discuss its potential role in vascular pathophysiology.
Export Options
About this article
Cite this article as:
Simo Cheyou R. Estelle, Bouallegue Ali and Srivastava K. Ashok, Ca2+/Calmodulin-Dependent Protein Kinase- II in Vasoactive Peptide- Induced Responses and Vascular Biology, Current Vascular Pharmacology 2014; 12 (2) . https://dx.doi.org/10.2174/1570161112666140226123139
DOI https://dx.doi.org/10.2174/1570161112666140226123139 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Flavonoids, Vascular Function and Cardiovascular Protection
Current Pharmaceutical Design Correlations Between Carotid IMT, Factor VIII Activity Level and Metabolic Disturbances: A Cardio-Vascular Risk Factor in the HIV Positive Persons
Current HIV Research Central Hemodynamics in Risk Assessment Strategies: Additive Value Over and Above Brachial Blood Pressure
Current Pharmaceutical Design Transthyretin Cardiac Amyloidosis and Aortic Stenosis: Connection and Therapeutic Implications
Current Cardiology Reviews Multi-Targeted Natural Products Evaluation Based on Biological Activity Prediction with PASS
Current Pharmaceutical Design Chemistry and Pharmacological Properties of Some Natural and Synthetic Antioxidants for Heavy Metal Toxicity
Current Medicinal Chemistry Current Pharmacological Treatment of Pulmonary Arterial Hypertension
Current Clinical Pharmacology Renin-Angiotensin-Aldosterone System Antagonists and the Prevention of Type 2 Diabetes Mellitus
Current Pharmaceutical Design Adipocytes and Abdominal Aortic Aneurysm: Putative Potential Role of Adipocytes in the Process of AAA Development
Current Drug Targets Lipoproteins, Stroke and Statins
Current Vascular Pharmacology Nutraceutical: A Drug, Dietary Supplement and Food Ingredient
Current Pharmacogenomics and Personalized Medicine Equilibrative Nucleoside Transporters in Fetal Endothelial Dysfunction in Diabetes Mellitus and Hyperglycaemia
Current Vascular Pharmacology Simvastatin and Other HMG-CoA Reductase Inhibitors on Brain Cholesterol Levels in Alzheimers Disease
Current Alzheimer Research Green Tea Polyphenols as an Anti-Oxidant and Anti-Inflammatory Agent for Cardiovascular Protection
Cardiovascular & Hematological Disorders-Drug Targets Therapeutic Application of Endothelial Progenitor Cells for Treatment of Cardiovascular Diseases
Current Stem Cell Research & Therapy From Physiome to Pathome: A Systems Biology Model of Major Depressive Disorder and the Psycho-Immune-Neuroendocrine Network
Current Psychiatry Reviews Screening of Early and Late Onset Alzheimer’s Disease Genetic Risk Factors in a Cohort of Dementia Patients from Liguria, Italy
Current Alzheimer Research Role of Focal Adhesion Kinase in Human Cancer: A Potential Target for Drug Discovery
Anti-Cancer Agents in Medicinal Chemistry Use of Human Embryonic Stem Cells to Understand Hematopoiesis and Hematopoietic Stem Cell Niche
Current Stem Cell Research & Therapy Does It Make Sense that Diabetes is Reciprocally Associated with Periodontal Disease?
Endocrine, Metabolic & Immune Disorders - Drug Targets